


ORAL PLATFORM PRESENTATION ABSTRACTS

International Congress of Parkinson's
Disease and Movement Disorders®



August 27-31, 2023
Copenhagen
DENMARK



International Parkinson and
Movement Disorder Society

2023 International Congress Oral Platform Presentations

Group 1: Pharmacology and Therapy

Monday, August 28, 13:45 - 14:45

Location: C1 M3, (Ground Floor)

1353

Effects of NE3107 anti-inflammatory treatment on motor activity and neurodegenerative features of Parkinson's disease in a marmoset monkey model

1388

Exercise and levodopa metabolism in Parkinson disease

1389

Motor complications in Parkinson's disease

1391

Predicting motor outcome and quality of life after subthalamic DBS for Parkinson's Disease: the role of standard screening measures and wearable-data

1407

Pharmacological combinations in early stages of Parkinson's disease and association with motor complications

1444

Analysis of the therapeutic potential of lKt-148009 in Parkinson's disease

1445

Tremor characteristics differentially respond to levodopa and subthalamic nucleus deep brain stimulation in Parkinson's disease

1500

Blood derived α -synuclein seeding in the course of Parkinson's Disease

1413

VALidation of models for assessing eligibility for referral for Device-Aided Treatment in Parkinson's disease (VALIDATE)

Group 2: Imaging and Technology

Monday, August 28, 13:45 - 14:45

Location: C1 M0, (Ground Floor)

1548

Machine learning selects common fMRI features of cognitive impairment in Parkinson's disease from cross-institution datasets

1550

Early-phase 18F-FP-CIT PET images: a promising imaging biomarker for predicting early dementia conversion in Parkinson's disease

1556

Comparison of the MIBG uptake in the major salivary glands between progressive supranuclear palsy/corticobasal syndrome and Parkinson's disease

1589

Altered nucleus accumbens functional connectivity precedes apathy in Parkinson's disease

1599

Machine learning diagnosis of parkinsonian syndromes: network approach with two different sites

1619

Application of multi-parametric diffusion MRI in detecting visual disturbances in advanced Parkinson's disease population

1758

Predictive model for Identification of device-aided therapy (DAT) Candidates in Parkinson's Disease (DELIST-PD Study)

1792

Positive and negative myoclonus monitoring using ambulatory surface EMG and 3D accelerometry

1795

Automatic Detection of Parkinson's Disease by Voice Analysis

Group 3: Surgery

Monday, August 28, 13:45 - 14:45

Location: Auditorium 10 - 11, (First floor)

1649

Novel utilization of deep brain stimulation in the pedunculo pontine nucleus for treatment of childhood-onset dystonia

1656

Improved Tremor Response to Focused Ultrasound Thalamotomy

1660

Outcomes of Focused Ultrasound Thalamotomy in Tremor Syndromes

1662

Long-term outcomes of deep brain stimulation for VPS16-related dystonia: A multi-center international study

1681

Moving beyond trial and error: a strategy for anatomically informed contact selection in subthalamic deep brain stimulation for Parkinson's disease.

1690

Single-center experience of deep brain stimulation (DBS) surgery in Malaysia

1695

Pallidal or subthalamic DBS for advanced Parkinson's disease in the era of high-resolution MRI

1705

Image-guided programming is useful in DBS for Parkinson's disease

1739

AI-Guided Microelectrode Recording for GPi DBS in Parkinson's disease

1741

Quantifying the value of multimodal MRI in outcomes prediction for STN DBS in PD

Group 4: Allied Healthcare, Physical Therapy, Rehabilitation and Quality of Life/Caregiver Burden

Monday, August 28, 13:45 - 14:45

Location: Auditorium 12, (First floor)

1849

Bilateral subthalamic nucleus deep brain stimulation in Parkinson's disease: preoperative predictors of speech worsening

1861

An international consensus statement for rehabilitation care in Parkinson's disease

1922

Factors influencing health-related quality of life of patients with spinocerebellar ataxia

1939

Age-associated changes in the striatal proteins in aging Asian-Indians

1945

Asian LRRK2 variants do not increase Likelihood Ratios derived from MDS prodromal Parkinson's Disease criteria in a community population

Group 5: Clinical Trials

Tuesday, August 29, 13:45 - 14:45

Location: C1 M0, (Ground Floor)

15

SpeechATAX: A rater blinded randomized controlled trial of intensive home-based biofeedback therapy for dysarthria in progressive ataxia

11

Continuous Subcutaneous Levodopa/Carbidopa Infusion With ND0612 For Patients With Parkinson's Disease And Motor Fluctuations: Results From The Phase 3 Randomized, Active-Controlled Boundless Study

55

Substantia Nigra blood-brain barrier opening in Parkinson's disease: PET (18F-Choline) evidence of parenchymal penetration

67

Clinic versus home dose optimization of apomorphine sublingual film in Parkinson's Disease: cross-study comparison of safety

71

Intercultural differences in patient and clinician perceptions of MDS-UPDRS in Parkinson's disease

78

In silico electrophysiology study reveals the modulating role of calcium channel on Subthalamic nucleus neuronal cells towards Parkinson's disease

84

Efficacy of a four-strain probiotic on gut dysbiosis, motor and non-motor symptoms in Parkinson's disease: a multicentre randomised controlled trial

109

Decreased occurrence of dyskinesia when combining amantadine to L-DOPA in early Parkinson disease (PD): the PREMANDYSK trial

134

Benefits of Physician-Pharmacist Collaboration on Patient Outcomes in Parkinson's Disease and Movement Disorders Clinic

Group 6: Parkinsonisms

Tuesday, August 29, 13:45 - 14:45

Location: C1 M1, (Ground Floor)

155

Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy

167

Laryngeal clinical biomarkers in atypical Parkinsonism - results from an international multicenter study

177

Disease progression in multiple system atrophy: the value of clinical cohorts with long follow-up

190

The value of volume of the subthalamic nucleus in diagnosis of progressive supranuclear palsy

205

Topography of cholinergic vulnerability correlates of PIGD motor deficits in DLB and PSP: A [18F]-FEOBV PET study

211

18F-Florzolotau PET Imaging Captures the Distribution Patterns and Regional Vulnerability of Tau Pathology in Progressive Supranuclear Palsy

212

18F-Florzolotau PET imaging of tau pathology in the living brain of patients with corticobasal syndrome

220

Neurofilament light chain, tau-PET and microglia-PET predict clinical progression in amyloid-negative corticobasal syndrome

222

Prognostic impact of frontal-lobe clinical bedside signs in progressive supranuclear palsy

223

Describing the syndrome: a comprehensive analysis of a large cohort of corticobasal syndrome with pathological correlation

Group 7: Cognition and Psychiatric Disturbances

Tuesday, August 29, 13:45 - 14:45

Location: C1 M2, (Ground Floor)

237

A vicious cycle of karyopherin abnormalities in synucleinopathies

264

A multicenter, matched case-control study of alpha-synuclein accumulation in the gastrointestinal tract of Parkinson's disease

426

Subtyping Parkinson's disease: Quality of life changes after subthalamic stimulation depend on nonmotor and motor symptoms

427

Assessing non-motor symptoms and associations with quality of life among patients in Korle-Bu Teaching Hospital, Ghana

429

Sleep seasonality in alpha-synucleinopathies: a comparative study with non-neurological sleep disorder patients

512

Non-motor Symptoms Progression in Parkinson's Disease. A 4-year Follow-up Study.

536

Sleep quality in GBA, LRRK2 and idiopathic Parkinson disease

560

Longitudinal assessment of evolution and plasma biomarkers for depression and anxiety in Parkinson's disease

Group 8: Functional Movement Disorders, Epidemiology and Rating Scales

Tuesday, August 29, 13:45 - 14:45

Location: C1 M3, (Ground floor)

589

Functional movement disorders in dopa-responsive dystonia – A case series with implications for diagnosis and treatment

621

National Luxembourg Sleep Study: An enriched, at risk, prodromal Parkinson's Disease cohort

Group 9: Hyperkinetic Movement Disorders I

Wednesday, August 30, 13:45 - 14:45

Location: C1 M0, (Ground Floor)

682

Unique consecutive order of brain atrophy in spinocerebellar ataxia type 3 (SCA3)

689

Systemic and intracellular iron starvation response in Friedreich's Ataxia

697

FGF14 repeat expansions: Case series of adult-onset cerebellar ataxia patients from Serbia

700

Intronic FGF14 GAA repeat expansions are a common cause of ataxia syndromes with neuropathy and bilateral vestibulopathy

718

Genetic and phenotypic characterization of ATX-FAT2 (SCA45) in three Indian families

724

Description of a series of GAA-FGF14 ataxia / SCA27b patients

836

Dystonic tremor as main manifestation of a large SCA21 family

844

Transcranial magnetic stimulation study in primary dystonia of presumed genetic etiology

845

Visual dysfunction of the Superior Colliculus in idiopathic Blepharospasm: a pilot study

Group 10: Hyperkinetic Movement Disorders II

Wednesday, August 30, 13:45 - 14:45

Location: C1 M1, (Ground Floor)

874

Longitudinal imaging of regional volumes, presynaptic terminals and glucose metabolism in brains of people with early Huntington's disease

883

24(S)-Hydroxycholesterol and cognition in Huntington's disease: results from two large patient cohorts (TRACK-HD and ENROLL-HD)

897

Hazard ratios of suicidality in a large Huntington disease population compared with controls:

marginal structural modeling of Enroll-HD registry data

918

Jaw opening myoclonus in Subacute Sclerosing Panencephalitis: A new phenotypic observation which may be a diagnostic clue

938

Epigenetic clock acceleration is linked to earlier onset and phenoconversion of Rapid-eye-movement sleep behavior disorder

965

An evaluation of NBI-827104 for essential tremor: results from a randomized, double-blind, placebo-controlled, dose-escalation, crossover study

967

Testing for alcohol responsivity in familial essential tremor

1011

Jerky dystonic hand revisited: post-stroke thalamic tremor

Group 11: Genetics and Metabolic Diseases

Wednesday, August 30, 13:45 - 14:45

Location: C1 M2, (Ground floor)

1031

Mosaic divergent repeat interruptions in X-linked dystonia-parkinsonism: stability over generations and time

1033

Striatal neurodegeneration in female carriers of the TAF1 Mutation Causing X-linked Dystonia-Parkinsonism

1034

Exome sequencing of 584 Chinese proband with brain calcification

1038

Combined GWAS of Dementia with Lewy Bodies, REM-Sleep Behavior Disorder, Parkinson's Disease and Alzheimer's Disease

1051

The role of RNA-carrying exosomes in synaptic physiology and in synucleinopathies

1061

Are GBA-Parkinson Disease patients' good candidates for Deep Brain Stimulation? A Longitudinal Multicentric study on a Large Italian Cohort

1082

Clinical Prediction of GBA Carrier Status in Parkinson's Disease

1137

Impaired Nt-acetylation and the Golgi, a new disease mechanism leading to autosomal recessive primary familial brain calcifications

1154

Cerebellar ataxia in Hypomyelinating Leukodystrophies: A case series

Group 12: Physiology

Wednesday, August 30, 13:45 - 14:45

Location: C1 M3, (Ground Floor)

1194

Alterations in Cortico-basal ganglia Directed Connectivity in Parkinsonism and during Therapeutic STN DBS

1202

Deep brain stimulation modulates subthalamic beta bursts related to movement velocity adjustments in Parkinson's disease

1210

Differences in brain activity and oscillatory responses in resting and re-emergent tremor in Parkinson's disease

1219

Enrollment phase sensing data from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) clinical trial

1234

Longitudinal recordings of subthalamic local field potentials show intra-subject consistency of beta-based physiomarkers in Parkinson's Disease

1240

Beta is jumping the queue: Temporal overlap of beta desynchronization and synchronization during rapid movement changes

1251

A human tissue engineered nigrostriatal system as a testbed for understanding PD pathophysiology and therapeutic development

1256

IP-RT-QulC Identify Disease-Specific Alpha-Synuclein Seeds in serum from patients with synucleinopathy

1292

Flavonoid intake and risk of Parkinson's Disease